Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Adenocarcinoma 2Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × Phlebotomy × Tumor-Agnostic × Clear all
NCT00507702 2019-04-18

Identification of Key Blood Molecular Markers for Immunotherapy

Stanford University

Terminated
191 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell, Neoplasms

NCT00547742 2010-07-20

Correlation of PET-CT Studies With Serum Protein Analysis

Stanford University

Completed
1,500 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡